Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA GENERAL:~1. 12 years of age or older~2. Signed written informed consent~3. Willingness and ability to comply with schedule for follow-up visits~4. Contact lens removal prior to evaluation and treatment~5. Candidates must also have two of the following criteria:~   1. Presence of central or inferior steepening on the Pentacam or Orbscan map consistent with Keratoconus.~  2. Axial topography consistent with keratoconus.~  3. Steepest keratometry (Kmax) value of 47.00D~INCLUSION CRITERIA FOR ECTASIA:~History of having undergone a keratorefractive procedure and 2 of the following criteria:~1. Steepening by topography, either Pentacam or Orbscan~2. Thinning of cornea~3. Shift in the position of thinnest portion of cornea~4. Change in refraction with increasing myopia~5. Development of myopic astigmatism~6. Development of irregular astigmatism~7. Loss of BSCVA~   EXCLUSION CRITERIA:~   I. Eyes classified as either normal or atypical normal 2. Corneal pachymetry 350 microns at the thinnest point measured by Pentacam in the eye to be treated 3. A history of chemical injury or delayed epithelial healing in the eye to be treated.~   4. Pregnancy (including plan to become pregnant) or lactation during the course of the study 5. A known sensitivity to study medications 6. Patients with nystagmus or any other condition that would prevent a steady gaze during the treatment 7. Inability to cooperate with diagnostic tests. 8. Patients with a concomitant condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.~   9. Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking treatment.~   10. Patients who are unable to remain supine and tolerate a lid speculum for an extended period of time.~   -

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Riboflavin drops - epithelium on or off (Type: OTHER): Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax

Based on this trial design, predict the completion outcome and termination type (if applicable).